These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24630522)

  • 21. Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran).
    Hamidi-Fard M; Makvandi M; Samarbaf-Zadeh A; Hajiani E; Shayesteh A; Masjedizadeh A
    Indian J Med Microbiol; 2013; 31(4):360-5. PubMed ID: 24064642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing.
    Ko SY; Oh HB; Park CW; Lee HC; Lee JE
    Clin Microbiol Infect; 2012 Oct; 18(10):E404-11. PubMed ID: 22757653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
    Kırdar S; Yaşa MH; Sayan M; Aydın N
    Mikrobiyol Bul; 2019 Apr; 53(2):144-155. PubMed ID: 31130119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B.
    Akman SA; Kose S; Halicioglu O
    Int J Infect Dis; 2010 Mar; 14(3):e236-9. PubMed ID: 19665408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
    Margeridon-Thermet S; Svarovskaia ES; Babrzadeh F; Martin R; Liu TF; Pacold M; Reuman EC; Holmes SP; Borroto-Esoda K; Shafer RW
    Antimicrob Agents Chemother; 2013 Jan; 57(1):343-9. PubMed ID: 23114756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.
    Salpini R; Svicher V; Cento V; Gori C; Bertoli A; Scopelliti F; Micheli V; Cappiello T; Spanò A; Rizzardini G; De Sanctis GM; Sarrecchia C; Angelico M; Perno CF
    Antiviral Res; 2011 Nov; 92(2):382-5. PubMed ID: 21920388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2.
    Kim JE; Lee SY; Kim H; Kim KJ; Choe WH; Kim BJ
    World J Gastroenterol; 2017 Jun; 23(23):4222-4232. PubMed ID: 28694662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
    Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
    J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance.
    Choi YJ; Kim HS; Lee SH; Park JS; Nam HS; Kim HJ; Kim CJ; Jeong DJ; Park KS; Baek KA
    Arch Virol; 2011 Sep; 156(9):1517-24. PubMed ID: 21594598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients.
    Fan J; Zhang Y; Xiong H; Wang Y; Guo X
    J Gen Virol; 2015 Mar; 96(Pt 3):663-670. PubMed ID: 25481755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.
    Ayres A; Yuen L; Jackson KM; Manoharan S; Glass A; Maley M; Yoo W; Hong SP; Kim SO; Luciani F; Bowden DS; Bayliss J; Levy MT; Locarnini SA
    J Viral Hepat; 2014 Nov; 21(11):809-17. PubMed ID: 24329944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing.
    Han Y; Zhang Y; Mei Y; Wang Y; Liu T; Guan Y; Tan D; Liang Y; Yang L; Yi X
    J Virol Methods; 2013 Nov; 193(2):341-7. PubMed ID: 23773806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation.
    Ji D; Liu Y; Li L; Xu Z; Si LL; Dai JZ; Li X; Wang L; Yao Z; Xin SJ; Chen GF; Xu D
    J Clin Virol; 2012 May; 54(1):66-72. PubMed ID: 22398037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple-site analysis of HBV drug-resistant mutations in 340 patients with chronic hepatitis B].
    Xu DP; Liu Y; Cheng J; Li XD; Dai JZ; Li L; Liang ZL; Bai L; Zhong YW; Xu ZH; Ren XQ; Zhang LX
    Zhonghua Gan Zang Bing Za Zhi; 2008 Oct; 16(10):735-8. PubMed ID: 18983768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigation of baseline antiviral resistance in treatment-naive chronic hepatitis B cases].
    Ergünay K; Kahramanoğlu Aksoy E; Simşek H; Alp A; Sener B; Tatar G; Us D; Hasçelik G
    Mikrobiyol Bul; 2013 Oct; 47(4):628-35. PubMed ID: 24237431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.